Posaconazole Intravenous and Tofacitinib Tablets
Determining the interaction of Posaconazole Intravenous and Tofacitinib Tablets and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Posaconazole may increase the blood levels of tofacitinib. You may experience increased side effects such as low blood cell counts, anemia, serious infections, and elevated blood lipid levels. Contact your doctor if you develop symptoms such as paleness, fatigue, dizziness, fainting, fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADJUST DOSE: Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of tofacitinib, which is metabolized by the isoenzyme. In study subjects, administration with the potent CYP450 3A4 inhibitor ketoconazole increased tofacitinib systemic exposure (AUC) by greater than 2-fold compared to administration of tofacitinib alone. Side effects including lymphopenia, neutropenia, anemia, serious infections, and hyperlipidemia may be increased.
MANAGEMENT: The dosage of tofacitinib should be reduced by 50% when used with potent CYP450 3A4 inhibitors. For example, the dose for patients receiving 10 mg twice daily should be reduced to 5 mg twice daily and the dose for patients receiving 5 mg twice daily should be reduced to 5 mg once daily. For patients receiving 11 mg once daily of the extended-release formulation, the dose should be reduced to 5 mg once daily of the immediate-release formulation.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
- Cerner Multum, Inc. "Australian Product Information." O 0
- "Product Information. Xeljanz (tofacitinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY.
Generic Name: posaconazole
Brand name: Noxafil
Synonyms: Posaconazole (oral/injection), Posaconazole
Generic Name: tofacitinib
Brand name: Xeljanz, Xeljanz XR
Synonyms: Tofacitinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Posaconazole Intravenous-Tofranil
- Posaconazole Intravenous-Tofranil injection
- Posaconazole Intravenous-Tofranil-PM
- Posaconazole Intravenous-Tol-Tab
- Posaconazole Intravenous-Tolazamide
- Posaconazole Intravenous-Tolbutamide
- Tofacitinib Tablets-Posaconazole Oral Suspension
- Tofacitinib Tablets-Posaconazole oral/injection
- Tofacitinib Tablets-Posaconazole Tablets
- Tofacitinib Tablets-PosiFlush flush
- Tofacitinib Tablets-Positive Skin Test Control - Histamine
- Tofacitinib Tablets-Posture